The FDA Panel Voted Yes on Peptides. Your Processor Didn’t.
An Advisory Panel Voted. The FDA Has Not Decided Anything.
On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides and recommended six of them for the 503A bulk drug substances list: BPC-157, KPV, TB-500, MOTS-c, epitalon and semax. Emideltide was rejected. Headlines the following week said peptides had been approved.
They have not been. Three details in that vote matter more to peptide payment processing than the headline does.
The margins were narrow. BPC-157, KPV and TB-500 passed eight votes to six with one abstention. MOTS-c passed seven to five with two abstentions. The FDA’s own scientific staff recommended against all seven, citing insufficient evidence on safety and effectiveness. And the committee is advisory: its recommendation is not binding, and adding a substance to the 503A list requires formal rulemaking that food and drug attorneys expect to take a year or more. The agency has more than two thousand public comments to work through first.
It is not FDA approval. It is not a finding that these peptides are safe or effective. It does not make anything legal to sell today that was illegal to sell last month. It is one step in a process that has several more, and the agency is free to reject it.
Merchants are asking about peptide payment processing this month for a reason that has nothing to do with the rulemaking calendar. Telehealth platforms and med spas read the same headlines, and several have already begun advertising compounded peptides as though the question were settled. Demand is moving faster than the regulation is, which is precisely the condition that produces frozen accounts.
There is a second calendar worth knowing. The committee has already scheduled a meeting before the end of February 2027 to consider five more peptides, including LL-37, GHK-Cu, dihexa acetate, melanotan II and pegylated mechano growth factor. This is a multi-year regulatory arc, not an event that concluded in July.
Your Processor Is Reading a Different Document
Underwriting does not track news cycles. It tracks whether a merchant is dispensing an approved drug against a valid prescription, and whether the entity doing the dispensing holds a license that makes it accountable for what it ships.
That is the line that decides peptide payment processing, and the advisory vote did not move it. A licensed 503A compounding pharmacy filling prescriptions written by a clinician sits on one side. An e-commerce store shipping vials labelled “research use only” to anyone with a card sits on the other, and has since long before this vote.
The distinction matters more than most merchants realise, because those two positions are not two grades of the same risk. They are different categories entirely. High risk means an acquirer will underwrite you at a price, usually with a reserve and tighter monitoring. Prohibited means no acquirer in the network will board you at any price, because the card brands do not permit the category. Unapproved pharmaceuticals sold direct to consumers have generally been treated as the second kind.
This is the part that surprises people. A merchant who has been processing quietly for two years often assumes that silence equals approval. It does not. Most peptide payment processing arrangements that appear to be working are simply arrangements that have not been reviewed yet, usually because volume has stayed low enough not to trigger one. The account is not approved for the category; it is unexamined.
That label is what underwriters look for, not what they miss. It signals a product being sold for human use while disclaiming human use, which is the exact pattern acquirers screen for. It reads as an attempt to sit outside a rule rather than inside one.
The Merchants Most Likely to Act on This News Are the Most Exposed
Here is the sequence worth avoiding. A seller reads that an FDA panel backed six peptides, treats it as permission, and does what any confident merchant does: expands the product page, raises ad spend, adds compounded-peptide language to the site, and starts converting at volume.
The processor’s review is not triggered by the vote. It is triggered by the volume. Rising deposits pull the account into a monitoring queue, someone reads the website, and the merchant is now visibly selling a category they were not boarded for.
When an account is frozen for a category mismatch, the hold typically covers funds already captured, not just future sales. Money from transactions that already settled can sit for weeks. A merchant who scaled on the headline can lose access to the proceeds of the exact growth that triggered the review.
Where the account sits changes how fast this happens. On an aggregator like Square, Stripe or PayPal, thousands of merchants share one underwriting relationship, so the platform manages risk by acting quickly and asking afterwards. On a dedicated merchant account, an acquirer underwrote you specifically and generally opens a conversation before it closes an account. Neither is a guarantee, but peptide payment processing on an aggregator carries materially less warning.
Termination carries a longer tail than the freeze does. A merchant terminated for misrepresenting what they sell can be listed on the card brand database that acquirers check during onboarding, and that listing is what makes the next application difficult. It is worth understanding how the brands classify and register high-risk merchants before growth makes the question urgent.
What Makes a Peptide Merchant Bankable
None of this means the category is permanently unbankable. It means bankability is decided by structure, not by headlines. Four things carry weight in peptide payment processing, and all four are verifiable by an underwriter without taking your word for anything.
Licensure that names you. A 503A compounding pharmacy is a regulated, inspected, state-licensed entity. That license is the single strongest signal available, because it means somebody with authority can revoke it. Underwriters treat accountability as collateral.
Prescriptions on file. Compounding is patient-specific by definition. A prescription trail converts a shipment from a consumer product into a dispensed medication, which is a different underwriting object entirely.
Accurate coding. A pharmacy boarded under a generic retail code is misclassified whether or not anyone has noticed yet, and misclassification is what surfaces during a review. Coding is worth getting right at boarding, not after. The same failure shows up across regulated verticals — it is the core of why med spa accounts get frozen despite operating legitimately.
Marketing that matches the file. Underwriters read the website. Disease claims, dosing guidance, or before-and-after outcome language on a product page can contradict the compliance posture the application described, and the site is the version they believe.
A processor who knows the category. An acquirer with no restricted-vertical experience will either decline the application or approve it and reverse that decision at the first review, which is the worse outcome because it happens after you have built volume on it. Peptide payment processing belongs with an underwriter who priced the risk deliberately rather than one who missed it.
None of those four things is a workaround. They are the ordinary requirements of a regulated category, and a merchant who meets them is not gaming an exception — they are simply legible to the people deciding.
If the FDA does adopt the recommendation, the merchants positioned to benefit are the licensed pharmacies that were already operating correctly. Nothing about the rulemaking is likely to make a gray-market storefront bankable. The path runs through licensure, and it always did.
Primary source for the committee’s remit and the 503A bulks list is the FDA’s Pharmacy Compounding Advisory Committee.
Frequently Asked Questions
No. An advisory committee recommended six of seven for the 503A compounding list. The FDA has not acted on that recommendation, and doing so requires rulemaking expected to take a year or more. Nothing about what you may lawfully sell changed in July 2026.
Generally yes. Licensed pharmacies are an established, underwritable category with their own coding and their own requirements. Peptide payment processing works for a pharmacy when the licensure, the prescription trail, the merchant category code and the website all describe the same business. Where applications fail is usually the last of those four, not the first.
Read the notice for the specific reason cited, because a category mismatch, a chargeback threshold and a documentation request are three different problems with three different paths. Do not keep processing into a frozen account while you sort it out. Get the reason in writing first.
Send Your Statement. We’ll Tell You How You Are Coded and Where the Risk Sits.
If you process in a regulated or restricted category, the merchant category code on your statement and the description on your application decide more than your rate does. Send Brookside one recent statement and we’ll tell you what code you’re boarded under, what that code implies to a risk reviewer, and whether your effective rate is what you were told it would be. The math takes us about fifteen minutes. Learn more about payment processing consumer protections from the CFPB.
Send Your Statement for Free ReviewNo obligation • No pressure • Response within one business day
See what a statement review looks like →